Immunotherapy combo for inoperable lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must be confirmed by a biopsy or tissue sample.
- You must be at least 18 years old and expected to live at least 3 more months.
- Your liver and kidney function must be within a certain range (checked by blood tests).
- You must have at least one tumor that can be measured on a scan.
- You cannot have had other cancer treatments in the past 4 weeks or have other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests combining two immunotherapy drugs (iparomlimab and tuvonralimab) with 2 or 4 cycles of chemotherapy before surgery for patients with stage II to IIIB non-small cell lung cancer that can be removed. It aims to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.